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ABSTRACT
Background: Abnormal body fat distribution and reduced
antioxidant status have been shown to be effective markers of
risk of cardiovascular disease (CVD).
Objective: The objective of this study was to determine the dif-
ferences in body fat distribution and antioxidant status in
healthy men (control subjects) and in men with CVD with or
without diabetes.
Design: An oral-glucose-tolerance test was performed and CVD
patients were subdivided into groups according to the presence
or absence of diabetes. Adipose tissue areas were calculated
from computed tomography scans made at the L1 and L4 verte-
brae. Fasting serum concentrations of lipids, testosterone,
insulin-like growth factor I, antioxidants, and plasma homocys-
teine were determined.
Results: There were no significant differences in mean age,
body mass index (in kg/m2), or blood pressure between the
groups. The visceral fat area at the L1 vertebra was nonsignifi-
cantly greater in CVD patients without diabetes than in control
subjects, whereas it was significantly greater in CVD patients
with diabetes than in control subjects at both the L1 and L4 ver-
tebrae. Both groups of CVD patients had higher plasma concen-
trations of homocysteine and lower serum insulin-like growth
factor I concentrations and superoxide dismutase activities than
did control subjects. Serum -carotene and lycopene concentra-
tions were lowest in the CVD patients with diabetes.
Conclusion: The concurrent presence of CVD and diabetes is
associated with a greater negative effect on the risk factors typi-
cally associated with significant declines in health status.
Am J Clin Nutr 2001;73:68–74.
KEY WORDS Visceral fat, antioxidants, diabetes, cardio-
vascular disease, Korean men
INTRODUCTION
In addition to the traditional risk factors for cardiovascular
disease (CVD) (hypertension, diabetes, smoking, and hypercho-
lesterolemia), abdominal obesity, impaired antioxidant status,
and hyperinsulinemia have been reported to be risk factors (1).
An elevated fasting insulin concentration is associated with
insulin resistance, which increases an individual’s risk of CVD
(2–4). Insulin resistance has also been reported to be closely
associated with visceral fat accumulation (5). Therefore, central
body fat distribution appears to be a greater risk factor for CVD
than does obesity itself (6). Men with angiographically con-
firmed CVD had a higher waist-to-hip ratio (WHR) and a higher
serum insulin concentration than did healthy men of similar ages
and body mass indexes (BMI; in kg/m2) (7, 8).
The serum -tocopherol concentration was inversely corre-
lated with WHR (r =  0.23, P = 0.0001) in healthy Swedish
adults (9). Carotenoids, glutathione peroxidase, superoxide dis-
mutase, and -tocopherol are known to protect serum lipopro-
teins and vascular endothelium against oxidative stress and lipid
peroxidation, which lead to atherosclerosis (10–12). Previous
studies indicated that the concentrations of antioxidants in
plasma and tissue were lower in patients with CVD than in a
healthy control group and that the -carotene concentration in
adipose tissue was significantly lower in patients with myocar-
dial infarction than in the control group (13).
It is well accepted that a poor antioxidant status promotes
free radical production and that such an increase in free radicals
correlates with increases in total homocysteine (tHcy) concen-
trations. An elevated tHcy concentration is thought to be a risk
factor for CVD and may accelerate the progression and the ini-
tial incidence of arteriosclerosis via direct cytotoxic effects on
endothelial cells or via LDL oxidation due to free radical gen-
eration (14–16). Moderate hyperhomocysteinemia is defined as
plasma concentrations of tHcy > 15–16 mol/L and has been
identified in 20–40% of patients with atherosclerotic vascular
disease (14, 17).
The risk of CVD is 2–3 times greater in men with diabetes
than in men without diabetes (13). It was observed that risk fac-
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tors such as hypertension, dyslipidemia, abdominal obesity, and
insulin resistance occur frequently in persons with diabetes. In
addition, the antioxidant defense system of such persons may be
damaged by oxidative stress after glycosylation (13). CVD
patients with abdominal obesity and insulin resistance may have
a higher prevalence of type 2 diabetes mellitus.
An increase in morbidity and mortality rates as a result of
CVD was observed in 1996 (18). However, little has been
reported about the effects of central visceral fat accumulation,
hyperinsulinemia, compromised antioxidant status, and elevated
plasma tHcy on the incidence and progression of CVD in Korean
men. We investigated whether there are differences in body fat
distribution and antioxidant status among 3 groups: healthy men,
CVD patients without diabetes, and CVD patients with diabetes.
SUBJECTS AND METHODS
Subjects
Fifty-six men with CVD (aged 30–69 y) were referred by the
Division of Cardiology, Yonsei Cardiovascular Center, Yonsei Sev-
erance Hospital, Seoul, Korea. The inclusion criteria required
angiographic evidence with ≥50% occlusion of one or more major
coronary arteries, previous myocardial infarction, or angina pec-
toris. The CVD patients were taking drugs such as blood pres-
sure–lowering agents, aspirin, and antithrombosis agents, but none
were taking drugs known to influence lipid concentrations. Just one
diabetic patient was already taking an oral hypoglycemic agent.
Sixty-four healthy men were selected for the control group
from volunteers who responded to advertisements for a nutrition
study conducted by the Clinical Nutrition Research Team at Yon-
sei University in 1998. All control subjects had normal glucose
tolerance and normal results on electrocardiograms and none had
a diagnosis of any type of CVD (including coronary heart disease,
stroke, and peripheral vascular disease) or cancer. All subjects
gave their informed consent before participating in the study. After
completing an oral-glucose-tolerance test, the CVD patients were
subdivided into 2 groups: subjects with (n = 26) and without
(n = 30) diabetes. The Institutional Review Board for Clinical
Research of the Yonsei University (Severance Hospital) approved
the study protocol and all subjects gave their informed consent.
Alcohol consumption, smoking status, dietary supplement
intake, and anthropometry
Alcohol consumption was calculated as the grams of ethanol
ingested per day and cigarette smoking data were reported as
the number of cigarettes smoked per day. The body heights and
weights of subjects in light clothing were measured and BMI
was computed. Waist and hip circumferences were measured
and the WHR was computed as an indication of the index of
body fat distribution. A survey was used to determine the use of
dietary supplements.
Computed tomography of the fat areas at the L1 and L4
vertebrae
To quantify fat area, all subjects underwent computed tomog-
raphy (CT) scanning with a High Speed Advantage 9800 Scan-
ner (General Electric, Milwaukee). Cross-sectional images were
made of the abdomen at the L1 and L4 vertebrae. Each slice was
analyzed for the cross-sectional area of fat by using a density
contour program available with the CT scanner. The parameters
for total abdominal fat density at the L1 and L4 vertebrae were
between 150 and 50 Hounsfield units. Total abdominal fat
area was divided into visceral and subcutaneous fat areas.
Blood collection and blood pressure measurement
Venous blood specimens were collected after a 12-h fast into
plain (for serum glucose, lipid, antioxidant, and hormone analyses)
or EDTA-treated (for tHcy analysis) tubes. The tubes for antioxi-
dant analysis were immediately covered with aluminum foil and
placed on ice in the dark until they arrived at the laboratory. Blood
pressure was read from the left arm while subjects remained seated.
An average of 3 measurements was recorded for each subject.
Serum lipids and lipoproteins
Serum total cholesterol, LDL cholesterol, and triacylglycerol
were measured with commercially available kits on a Hitachi
7150 Autoanalyzer (Hitachi Ltd, Tokyo). After precipitation of
serum chylomicrons, LDL, and VLDL with a precipitating agent,
the HDL cholesterol left in the supernate was measured with an
enzymatic method.
Oral-glucose-tolerance test
All subjects ingested a 75-g glucose solution after an overnight
fast. Serum samples were collected before and 30, 60, 90, and
120 min after the glucose load. The criteria developed by the
World Health Organization Expert Committee on Diabetes Melli-
tus was used to determine whether subjects had diabetes [a fasting
glucose concentration >7.7 mmol/L (140 mg/dL) and a 2-h glu-
cose concentration >11.1 mmol/L (200 mg/dL)]. Glucose was
measured with a glucose oxidase method by using a glucose ana-
lyzer (Beckman Instruments, Irvine, CA). Insulin was measured
by using an immunoradiometric assay (Dainabot, Tokyo) and C-
peptide was measured by using a radioimmunoassay with com-
mercial kits from Immuno Nucleo Corporation (Stillwater, MN).
Each glucose, insulin, and C-peptide response was calculated as
the area under the response curve.
Hormones
Serum testosterone was measured with a kit from Immuchem
(Diagnostics Product Corp, Los Angeles). Serum insulin-like
growth factor I (IGF-I) was measured with an immunoradiomet-
ric assay kit from Diagnostic System Laboratories (Webster, TX).
Serum sex hormone binding globulin and plasma total
homocysteine
Radioimmunoassays were used to measure serum sex hor-
mone binding globulin (SHBG). The free androgen index was
the ratio of the percentage of testosterone to moles of SHBG
(19). Plasma tHcy was analyzed with a Bio20 Autoloader
Amino Acid Analyzer (Pharmacia Biotech, Cambridge, United
Kingdom) with a postcolumn ninhydrin reaction system
according to the modified method of Anderson et al (20) and
Ueland et al (21).
Serum retinol, carotenoids, and tocopherols
Reversed-phase HPLC was used to determine retinol, caro-
tenoids, and tocopherols in serum simultaneously as described
by Yeum et al (22), Bankson et al (23), and McCrehan (24). The
HPLC system consisted of an Alliance Waters 2690 separation
module, a Waters 996 photodiode array detector, a Waters 474
scanning fluorescence detector, a C18 Symmetry 3.9  15 cm
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column, and a PDA Millennium for version 2.15 DATA STA-
TION (Waters, Milford, MA). The 474 scanning fluorescence
detector was set at 294 nm for the detection of tocopherols.
Retinol, carotenoids, and tocopherols were reported as serum
concentrations uncorrected or corrected for the sum of serum
cholesterol (mmol/L) and serum triacylglycerol (mmol/L) as
suggested by Thurnham et al (25).
Serum antioxidant enzymes and malondialdehyde
Glutathione peroxidase activity was determined by using the
coupled enzyme procedure at 340 nm, with hydrogen peroxide as
substrate, according to Paglia and Valentine (26) and Deagen et
al (27). Superoxide dismutase activity was estimated by the
method of Marklund and Marklund (28) and Sheri et al (29).
Malondialdehyde was assayed according to the fluorometric
method described by Buckingham (30).
Statistical analysis
Statistical analyses were conducted with SPSS/PC+ (version
7.0; SPSS Inc, Chicago). For descriptive purposes, values are
presented as means ± SEMs. To determine differences in body
fat distribution and in antioxidant status between the 3 groups,
the sample sizes were selected on the basis of the following
assumptions: the present study would have 80% power to detect
a 20% relative difference in tHcy concentrations between the
healthy men and the 2 CVD patient groups ( = 0.05, two-
tailed). Because these variables were reportedly 20% higher in a
group of CVD patients than in a healthy group (31), differences
between groups were evaluated by performing an analysis of
variance followed by the Bonferroni test. A P value < 0.05 was
considered to indicate statistical significance.
RESULTS
Alcohol consumption, cigarette smoking, and vitamin 
supplementation
Twenty-eight percent of the control subjects, 33% of the CVD
patients without diabetes, and 15% of the CVD patients with dia-
betes were current smokers. Fifty-eight percent of the control
subjects, 47% of the CVD patients without diabetes, and 38%
of the CVD patients with diabetes typically consumed > 5 g
ethanol/d. Fifty-six percent of the control subjects, 30% of the
CVD patients without diabetes, and 46% of the CVD patients with
diabetes supplemented their diet with a multivitamin (B complex
and vitamin C) preparation; however, none had taken any sup-
plement for 1 mo before blood collection.
Age, BMI, blood pressure, and body fat distribution
There were no significant differences in age, BMI, or sys-
tolic or diastolic blood pressure between the 3 groups (Table 1).
CVD patients with diabetes showed the highest mean WHR
values. Visceral fat area at the L1 vertebra tended to be greater
in the CVD patients without diabetes than in the control group.
CVD patients with diabetes had a significantly greatest vis-
ceral fat area at the L1 and L4 vertebrae than did the control
subjects (Figure 1).
Serum lipid, glucose, insulin, and C-peptide concentrations
Serum HDL-cholesterol concentrations were lowest in the
CVD patients with diabetes (Table 2). Of the 3 groups, CVD
patients with diabetes had the highest atherogenic index, fasting
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TABLE 1
Age, anthropometric measures, and fat areas at different sites of the body
in healthy men and in CVD patients with or without diabetes1
Control Nondiabetic Diabetic
subjects CVD patients CVD patients
(n = 64) (n = 30) (n = 26)
Age (y) 52.9 ± 0.93 53.2 ± 1.37 55.0 ± 1.50
BMI (kg/m2) 24.3 ± 0.37 24.8 ± 0.46 25.1 ± 0.40
WHR 0.92 ± 0.01 0.93 ± 0.01 0.95 ± 0.012
Systolic BP (mm Hg) 126.8 ± 2.66 132.8 ± 2.43 134.4 ± 2.82
Diastolic BP (mm Hg) 86.2 ± 2.71 82.6 ± 2.38 84.5 ± 2.03
L1 vertebra
Total fat (cm2) 216.1 ± 10.6 241.6 ± 12.0 243.7 ± 12.0
Subcutaneous fat (cm2) 76.8 ± 4.20 77.0 ± 4.43 74.1 ± 4.10
L4 vertebra
Total fat (cm2) 252.0 ± 9.25 257.4 ± 9.80 271.4 ± 11.1
Subcutaneous fat (cm2) 131.4 ± 5.30 137.3 ± 7.40 133.5 ± 6.10
1 x– ± SEM. WHR, waist-to-hip ratio; CVD, cardiovascular disease; BP,
blood pressure.
2 Significantly different from control subjects, P < 0.05 (ANOVA fol-
lowed by the Bonferroni test).
FIGURE 1. Mean (± SEM) visceral fat area and the ratio of visceral
to subcutaneous fat area at the L1 and L4 vertebrae in healthy men
(, control subjects; n = 64) and in CVD patients with (; n = 26) or
without (; n = 30) diabetes. 2Significantly different from control sub-
jects, P < 0.05 (ANOVA followed by the Bonferroni test).
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glucose concentration, and glucose response area. Response
areas of insulin and C-peptide were significantly greater in the
CVD patients without diabetes than in the control group.
SHBG, antioxidant enzyme activity, and plasma total 
homocysteine
The mean testosterone concentration was lower in the 2 groups
of CVD patients than in the control group, but not significantly so
(Table 3). Serum IGF-I concentrations were significantly lower
in the 2 groups of CVD patients than in the control subjects.
Serum SHBG, glutathione peroxidase, the free androgen index,
and malondialdehyde were not significantly different between the
3 groups. Serum superoxide dismutase activities were signifi-
cantly lower in the 2 groups of CVD patients than in the control
subjects. tHcy concentrations were significantly higher in the
2 groups of CVD patients than in the control group (Figure 2).
Serum retinol, carotenoids, and tocopherols
There were no significant differences in uncorrected and
lipid-corrected serum concentrations of -carotene, retinol, and
- or -tocopherol between the 3 groups (Table 4). The cor-
rected and uncorrected serum cryptoxanthin concentrations were
lower in the CVD patients with diabetes than in the control sub-
jects, but not significantly so. The CVD patients with diabetes
had the lowest uncorrected and lipid-corrected lycopene concen-
trations, and uncorrected -carotene concentrations in this group
were lower (NS) than in the control group (Figure 3).
DISCUSSION
The results indicate that visceral fat accumulation is higher in
CVD patients than in healthy men of similar ages and BMIs and
that excessive visceral fat accumulation may accelerate the pro-
gression of type 2 diabetes mellitus. Visceral fat accumulation
induces insulin resistance, which encourages pancreatic -cells
to secrete more insulin to maintain normal glucose metabolism.
Thus, hyperinsulinemia results, which exacerbates insulin resis-
tance and further increases the accumulation of upper body fat
(4). Excessive accumulation of visceral fat may result in a rela-
tive deficiency of insulin, the secretion of which is insufficient to
regulate insulin resistance and leads to impaired glucose toler-
ance and potentially to type 2 diabetes mellitus (32, 33).
Compared with the healthy control group with normal glu-
cose tolerance, the CVD patients with diabetes showed severe
insulin resistance, resulting in hyperglycemia when insulin con-
centrations were not maintained. The similar response areas of
C-peptide and insulin in the control subjects and the CVD
patients with diabetes indicate that further visceral fat accumu-
lation and a relative deficiency of insulin may lead to a greater
incidence of type 2 diabetes mellitus in CVD patients. This
suggests that further visceral fat accumulation and a relative
deficiency of insulin in those with CVD may lead to a greater
incidence of type 2 diabetes mellitus.
Insulin resistance has been reported to influence lipoprotein
lipase activity, lipoprotein metabolism, and glucose metabolism
(4). Decreased lipoprotein lipase activity due to insulin resis-
tance may delay triacylglycerol-rich lipoprotein uptake and
decrease HDL-cholesterol formation. Another study reported
that insulin resistance accelerated HDL-cholesterol catabolism,
which led to a decrease in serum HDL-cholesterol concentra-
tions (34). In addition to insulin resistance, serum testosterone
concentrations in men were positively related to serum HDL
cholesterol and were presumably related to the regulation of
hepatic lipase activity (35).
An elevated serum testosterone concentration in men increases
the number of -receptors in visceral fat cells and the activity of
hormone-sensitive lipase, leading to fat mobilization (36). Growth
hormone activity is also more apparent in visceral than in subcu-
taneous fat and it accelerates the lipolysis of visceral fat in the
presence of testosterone. In the present study, IGF-I and testos-
terone concentrations were significantly different between the
control subjects and the CVD patients with and without diabetes.
These differences in hormone concentrations may partly reflect
the difference in visceral fat area between the CVD patients with
or without diabetes.
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TABLE 2
Serum lipids, glucose, insulin, and C-peptide and responses to a 75-g
oral-glucose-tolerance test in healthy men and in CVD patients with or
without diabetes1
Control Nondiabetic Diabetic
subjects CVD patients CVD patients
(n = 64) (n = 30) (n = 26)
Triacylglycerol (mmol/L) 1.67 ± 0.1 1.78 ± 0.16 1.79 ± 0.24
Total cholesterol (mmol/L) 5.14 ± 0.12 4.90 ± 0.17 4.80 ± 0.18
HDL cholesterol (mmol/L) 1.29 ± 0.04 1.10 ± 0.05 1.00 ± 0.052
LDL cholesterol (mmol/L) 3.09 ± 0.10 2.98 ± 0.16 2.98 ± 0.18
Atherogenic index3 3.16 ± 0.13 3.63 ± 0.20 4.05 ± 0.262
Total:HDL cholesterol 4.16 ± 0.13 4.63 ± 0.20 5.05 ± 0.262
LDL:HDL cholesterol 2.52 ± 0.11 2.81 ± 0.16 3.12 ± 0.222
Fasting concentration
Glucose (mmol/L) 5.44 ± 0.09 5.49 ± 0.17 6.90 ± 0.332,4
Insulin (pmol/L) 59.3 ± 4.36 61.4 ± 5.49 77.4 ± 13.4
C-peptide (g/L) 0.85 ± 0.04 0.97 ± 0.08 1.03 ± 0.11
Response area
Glucose (mmol·h/L) 16.2 ± 3.78 17.1 ± 0.49 23.1 ± 0.972
Insulin (pmol·h/L) 607.1 ± 31.7 949.6 ± 161.22 643.4 ± 73.2
C-peptide(g·h/L) 3.24 ± 0.25 4.58 ± 0.602 3.69 ± 0.63
1 x– ± SEM. CVD, cardiovascular disease.
2 Significantly different from control subjects, P < 0.05 (ANOVA fol-
lowed by the Bonferroni test).
3 (Total cholesterol  HDL cholesterol)/HDL cholesterol.
4 Significantly different from nondiabetic CVD patients, P < 0.05.
TABLE 3
Sex hormones and antioxidant enzyme activities in healthy men and in
CVD patients with or without diabetes1
Control Nondiabetic Diabetic
subjects CVD patients CVD patients
(n = 64) (n = 30) (n = 26)
Testosterone (nmol/L) 18.4 ± 0.66 17.3 ± 1.12 15.5 ± 1.22
SHBG (nmol/L) 52.8 ± 2.60 55.7 ± 5.38 48.1 ± 3.88
Free androgen index2 39.7 ± 2.74 35.3 ± 2.40 34.0 ± 2.42
IGF-I (g/L) 142.4 ± 7.68 72.3 ± 15.53 77.4 ± 17.13
Glutathione peroxidase 38.9 ± 1.23 38.9 ± 1.49 35.9 ± 1.59
(nmol NADPH/mg albumin)
Malondialdehyde (nmol/mL) 4.32 ± 0.19 4.45 ± 0.41 4.56 ± 0.45
1 x– ± SEM. CVD, cardiovascular disease; SHBG, sex hormone binding
globulin; IGF-I, insulin-like growth factor I.
2 Ratio of the percentage of testosterone to moles of SHBG.
3 Significantly different from control subjects, P < 0.05 (ANOVA fol-
lowed by the Bonferroni test).
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The CVD patients without diabetes had moderate hyperhomo-
cysteinemia (mean tHcy concentration: 15.1 mol/L), whereas
the CVD patients with diabetes had mild hyperhomocysteinemia
(mean tHcy concentration: 13.1 mol/L). It has been suggested
that tHcy may have direct cytotoxic effects or produce free radi-
cals that can result in endothelial damage and dysfunction (14).
An increase in free radical production contributes to oxidative
stress and exhausts the antioxidant system. Therefore, a high
tHcy concentration may be associated with low antioxidant
capacity (12, 14). In the present study, hyperhomocysteinemic
CVD patients with or without diabetes had lower superoxide dis-
mutase activity than did the control subjects. Superoxide dismu-
tase, a major antioxidant enzyme, catalyzes the dismutation of
superoxide anions to hydrogen peroxide and oxygen. The antiox-
idant defense system includes enzymatic and nonenzymatic
antioxidants. The most prominent nonenzymatic antioxidants are
vitamins E and C and carotenoids in the cytoplasm and lipid
membranes of cells (37).
-Carotene is a fat-soluble carotenoid and antioxidant that is
well known for its relation to atherosclerosis. -Carotene is con-
centrated in lipoprotein fractions such as HDL and LDL and
accumulates in atherosclerotic plaques (38, 39). It is well estab-
lished that high serum -carotene concentrations may protect
against endothelial damage by decreasing cholesterol uptake into
those cells and that -carotene inhibits atherosclerotic lesion for-
mation (39, 40).
In the present study, serum -carotene concentrations were
associated with physiologic and lifestyle factors, including
carotenoid intake, sex, age, BMI, and smoking status (41, 42).
The lower serum -carotene concentration in CVD patients
without diabetes than in the control group may have been related
not only to CVD itself, but also to this group’s lower carotenoid
intakes and current smoking status. The lower serum concentra-
tions of -carotene and lycopene in the CVD patients with dia-
betes than in the other 2 groups may have resulted from the
increased oxidative stress due to diabetes rather than to behav-
ioral or dietary choices. Persons with diabetes appear to be more
susceptible to ambient oxidative stress and might be under greater
oxidative stress than are persons without diabetes because of
glycosylation followed by oxidation processes (13).
Oxidative stress affects the peroxidation of polyunsaturated
fatty acids in LDL and exhausts ubiquinone-10 as well as vita-
min E and carotenoids, including lycopene, cryptoxanthin, and
lutein (44). Each of these compounds, singly, contributes little to
the resistance to LDL oxidation, but collectively may contribute
a great deal. Therefore, ingestion of a combination of different
antioxidants rather than of a single micronutrient may have a bet-
ter effect against LDL oxidation (43).
In summary, the male CVD patients in the present study had
greater visceral fat accumulation and insulin and tHcy concentra-
tions and lower IGF-I, superoxide dismutase, and -carotene con-
centrations than did the control subjects, who were healthy men
matched for age and BMI. In addition, the CVD patients with dia-
betes had the greatest visceral fat areas and tHcy concentrations
and the lowest serum concentrations of HDL cholesterol and
carotenoids of the 3 groups. Given the significant differences
observed between the 3 groups, lifestyle modifications such as
smoking cessation, reductions in abdominal fat, and consumption
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TABLE 4
Serum concentrations of carotenoids, retinol, and tocopherol in healthy
men and in CVD pateints with or without diabetes1
Control Nondiabetic Diabetic
subjects CVD patients CVD patients
(n = 64) (n = 30) (n = 26)
Uncorrected concentrations
-Carotene (mol/L) 0.06 ± 0.01 0.06 ± 0.01 0.05 ± 0.01
Retinol (mol/L) 4.53 ± 1.50 4.90 ± 1.31 4.12 ± 0.97
Cryptoxanthin (mol/L) 1.50 ± 0.16 1.31 ± 0.19 0.97 ± 0.13
-Tocopherol (mol/L) 24.7 ± 1.87 25.7 ± 2.83 29.9 ± 3.14
-Tocopherol (mol/L) 2.95 ± 0.30 3.24 ± 0.57 2.84 ± 0.47
Lipid-corrected concentrations
-Carotene (mol/mmol) 0.01 ± 0.001 0.01 ± 0.001 0.01 ± 0.001
-Carotene (mol/mmol) 0.19 ± 0.02 0.14 ± 0.02 0.12 ± 0.02
Retinol (mol/mmol) 0.72 ± 0.08 0.76 ± 0.07 0.64 ± 0.07
Cryptoxanthin (mol/mmol) 2.34 ± 0.25 2.01 ± 0.24 1.55 ± 0.25
Lycopene (mol/mmol) 1.14 ± 0.12 0.93 ± 0.17 0.65 ± 0.133
-Tocopherol (mol/mmol) 3.91 ± 0.33 4.07 ± 0.51 4.72 ± 0.55
-Tocopherol (mol/mmol) 0.47 ± 0.05 0.51 ± 0.09 0.43 ± 0.07
1 x– ± SEM. CVD, cardiovascular disease.
2 Each concentration of vitamins and carotenoids was divided by the
sum of cholesterol and triacylglycerol (mmol/L).
3 Significantly different from control subjects, P < 0.05 (ANOVA fol-
lowed by the Bonferroni test).
FIGURE 2. Mean (± SEM) plasma homocysteine concentrations and
serum total superoxide dismutase (SOD) activity in healthy men (,
control subjects; n = 64) and in CVD patients with (; n = 26) or with-
out (; n = 30) diabetes. 2Significantly different from control subjects,
P < 0.05 (ANOVA followed by the Bonferroni test).
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of antioxidant-rich foods are recommended to delay the progres-
sion of CVD and to maintain a healthy life. In addition, given the
significantly lower serum antioxidant concentrations in the CVD
patients than in the control subjects, it may be prudent for
patients with CVD to supplement their diet with antioxidants
such as ubiquinone-10, vitamins E and C, and mixed carotenoids,
including -carotene, lycopene, cryptoxanthin, and lutein.
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